On demand webinar: What should we be telling relatives of people with type 1 diabetes
In the sixth of our 2022 ABCD webinar series, please join Dr Parth Narendran to discuss 'What should we be telling relatives of people with type 1 diabetes?
The type 1 diabetes landscape is rapidly changing on many fronts. One of them is in the delay and prevention arena. The last few years have seen unprecedented changes in this space and we are approaching a time when therapies to delay type 1 diabetes may become available.
This webinar will bring the audience up to speed with progress in this area and concentrate on screening to identify people at risk of type 1 diabetes to whom these therapies can be offered. Since there is a significant genetic contribution to the development of type 1 diabetes, it is likely that family members will be some of the first to step forward to ask about and participate in screening programmes. This webinar will outline some of the information we should be passing on to them.
is meeting has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 1 category 1 (external) credit (ref: 13628
Speakers
-
Professor Rob Andrews
Rob Andrews is an Associate Professor at the University of Exeter, an Honorary Consultant Physician at Musgrove Park Hospital Taunton. He is one of the co-founders of EXTOD, a group that aims to provide evidence-based support for people with type 1 diabetes to undertake safe and effective exercise, and to enjoy its associated health benefits.
At the University he leads a group that researches how to encourage and support patients with diabetes to exercise. At Musgrove park hospital he runs specialist adult, adolescent and paediatric sports clinics to give advice to sports men, women and children who have Type 1 diabetes -
Professor Parth Narendran
Professor of Diabetes Medicine
Parth's research interest focusses on understanding the autoimmune destruction of insulin secreting beta cells that lead to type 1 diabetes and exploring how this process can be modulated. He is part of a national effort to explore the feasibility and acceptability of early surveillance programmes for pre-type 1 diabetes and is also exploring which therapies are best tested in the prevention arena.
He leads the T1D clinical service at the QE Hospital in Birmingham, supporting the islet and pancreas transplant, DAFNE, transition and exercise services.
